论文部分内容阅读
选病理分期T1,T2的膀胱癌病人60例,随机分成3组进行治疗。试验组A[经尿道膀胱肿瘤切除(TURBT)+光动力学治疗(PDT)]17例和试验组B(TURBT+PDT+膀胱内灌注化疗)15例,常规治疗对照组(TURBT+膀胱内灌注化疗)28例。试验组A和B(PDT组)在口服光敏剂CDHS801(200 mg/50 kg)24 h后进行PDT,能量密度为50 J/cm2。72 h后行TURBT手术,治疗期间不避光。试验组患者分别进行膀胱内灌注化疗或者不进行内膀胱灌注化疗,对照组按照常规治疗方式进行TURBT手术和膀胱内灌注化疗。研究结果表明,试验组A的患者生活质量显著优于对照组(P<0.05);试验组A和B患者的肿瘤复发率也显著低于对照组(P<0.05);而5年生存率和肿瘤进展率两项指标试验组与对照组相比无统计学差异。所以,在治疗T1,T2期膀胱癌时,作为常规手术切除的辅助治疗,术前进行PDT治疗与术后行膀胱内灌注化疗相比,可能存在肿瘤复发率低、患者生存率以及患者生活质量有所提高的优势。
Select the pathological stage T1, T2 of bladder cancer patients 60 cases were randomly divided into three groups for treatment. 17 cases of TURBT + PDT in trial group A and 15 cases of TURBT + PDT + intravesical instillation chemotherapy (TURBT + intravesical chemotherapy) 28 cases. The experimental group A and B (PDT group) received PDT after oral photosensitizer CDHS801 (200 mg / 50 kg) for 24 h, and TURBT was operated after the energy density was 50 J / cm2.72 h. Patients in the experimental group were treated with intravesical chemotherapy or intravesical instillation chemotherapy, respectively. The control group received TURBT and intravesical chemotherapy according to the conventional treatment. The results showed that the quality of life of patients in experimental group A was significantly better than that in control group (P <0.05). The tumor recurrence rates in experimental group A and B were also significantly lower than those in control group (P <0.05) Tumor progress rate of two indicators test group and the control group, no significant difference. Therefore, in the treatment of T1 and T2 bladder cancer, as a routine surgical resection adjuvant therapy, preoperative PDT treatment compared with postoperative intravesical chemotherapy, there may be tumor recurrence rate, patient survival and quality of life of patients Has the advantage of improvement.